Core Insights - The TUSCANY study has been initiated to evaluate the combination of tuspetinib (TUS), venetoclax (VEN), and azacitidine (AZA) for newly diagnosed acute myeloid leukemia (AML) patients [1][2] - Tuspetinib is positioned as a frontline therapy for AML, particularly for patients who are ineligible for intensive chemotherapy, and has shown favorable safety and broad clinical activity [2][3] - The trial aims to enroll 18-24 patients across 12 clinical sites in the U.S. by mid to late 2025, with a focus on various dosing schedules of TUS [4] Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for hematologic malignancies, with a pipeline that includes tuspetinib and luxeptinib [6] - Tuspetinib is an oral kinase inhibitor that targets multiple kinases and has demonstrated efficacy both as a monotherapy and in combination therapy for relapsed or refractory AML [6] - The company aims to address unmet medical needs in oncology, particularly in hematology, by enhancing the efficacy of existing therapies without overlapping toxicities [6]
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy